TY - BOOK
T1 - The Cost and burden of eye diseases and preventable blindness
AU - Deloitte Access Economics
AU - Bilgrami, Anam
AU - Cheung, Simone
AU - Pezzullo, Lynne
AU - Tay-Teo, Kiu
PY - 2013
Y1 - 2013
N2 - Conducted by Novartis, The European Forum Against Blindness (EFAB) and Deloitte Access Economics, "The Cost and Burden of Eye Diseases and Preventable Blindness" study quantified the economic impact of vision loss by analyzing the top four eye diseases responsible for vision loss: glaucoma, diabetic retinopathy, cataracts, and wet age-related macular degeneration (AMD), which, in the EU alone, affects one in 10 people. The study also analyzed the cost-effectiveness of interventions to prevent them. A total of 14 countries were included in the study: Australia, Argentina, Denmark, France, Germany, Ireland, Italy, Mexico, Poland, Slovak Republic, Spain, Sweden, Switzerland and the UK.
AB - Conducted by Novartis, The European Forum Against Blindness (EFAB) and Deloitte Access Economics, "The Cost and Burden of Eye Diseases and Preventable Blindness" study quantified the economic impact of vision loss by analyzing the top four eye diseases responsible for vision loss: glaucoma, diabetic retinopathy, cataracts, and wet age-related macular degeneration (AMD), which, in the EU alone, affects one in 10 people. The study also analyzed the cost-effectiveness of interventions to prevent them. A total of 14 countries were included in the study: Australia, Argentina, Denmark, France, Germany, Ireland, Italy, Mexico, Poland, Slovak Republic, Spain, Sweden, Switzerland and the UK.
UR - https://www.novartis.cz/cs/node/10291
M3 - Commissioned report
BT - The Cost and burden of eye diseases and preventable blindness
PB - Deloitte
CY - Sydney
ER -